Moatly / Stocks / HALO

Halozyme Therapeutics Inc (HALO) — what is it worth?

$102.98 · $11.7B market cap · Biotechnology
Scored from reported financial statements. Data as of 2026-11-11.
Moat
73
Durability of advantage
Management
95
Returns and capital use
Margin of safety
57
Price against value
Buy price
$114.53
Consensus of three methods
Intrinsic value
$117.90
What the business is worth
Margin of safety price
$58.95
Intrinsic value less 50%
10-CAP price
$72.55
Ten times owner earnings
Payback time price
$114.53
Eight years of free cash flow
Moatly AI Insight

Halozyme Therapeutics Inc is scored 73 for moat and 95 for management. The management score rests on a return on invested capital of 23.2% and a gross margin of 83.6% — figures that describe a business turning capital into profit efficiently. The balance sheet carries debt at 43.89x equity, which magnifies both the returns above and the risk beneath them. The solid moat and exceptional management are not the same judgement, and the gap between them is where the argument about this business sits.

The valuation runs on assumptions chosen to understate rather than flatter. Growth is modelled at 15.0% a year, below the 39.0% actually measured over the last decade — the model caps growth rather than extrapolating a good run forwards. The exit multiple assumed is 30.0x. That produces an intrinsic value of $117.90, a 10-CAP price of $72.55 and a payback time price of $114.53, with the value zone set at the highest of the three, $114.53. Today's price of $102.98 sits inside that zone.

A business scoring this well, trading inside its value zone, is the combination the framework exists to find — which is also the reason to check why the market disagrees. A margin of safety score of 57 describes the cushion, not the certainty.

Key figures

Price$102.98
Market cap$11.7B
P/E ratio26.2x
Return on invested capital23.2%
Gross margin83.6%
Debt to equity43.89x
Free cash flow yield8.0%
Growth rate used15.0%
Growth rate measured39.0%
Exit multiple assumed30.0x

How it compares

CompanyMoatBuy price
Bio-Techne (TECH)50$20.56
Jazz Pharmaceuticals Plc (JAZZ)53$351.09
Alnylam Pharmaceuticals (ALNY)72$297.00
Incyte (INCY)88$52.24

Be in the know

Subscribe to our Substack for deeper insights on value plays.

Subscribe free

Run your own assumptions

Every number above is built on assumptions that can be changed. In Moatly you can move the growth rate, the exit multiple and the margin of safety and watch every figure recalculate, so you are testing your own view of Halozyme Therapeutics Inc rather than accepting ours.

Download on the App StoreGet it on Google Play

Not investment advice. Estimates only, built on stated assumptions that could be wrong. Figures are drawn from reported financial statements and were current as of the date shown. Do your own research.